Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 11th Mar 2013 07:23

Admiral Group: Berenberg ups target price from 1000p to 1060p, but still recommends selling.Amlin: Westhouse Securities raises target price from 440p to 455p, but downgrades from add to neutral.Anite Group: Invetsec downgrades from buy to hold with a target price of 157p.Aviva: Citigroup reduces target price from 479p to 432p reiterating its buy recommendation. Bank of America shifts target price from 330p to 350p, while its neutral rating is maintained.Avocet Mining: Investec cuts target price from 28.60p to 24p and keeps a hold recommendation.Babcock: JP Morgan ups target price from 1120p to 1230p, while maintaining an overweight rating.Bovis Homes: UBS increases target price from 560p to 700p retaining a neutral rating.BP: Deutsche Bank moves target price from 500p to 520p, while leaving its buy recommendation unaltered.British American Tabacco: Investec raises target price from 3350p to 3800p reiterating a buy recommendation.Capita: Westhouse Securities takes target price from 661p to 755p, while maintaining a sell recommendation.CAP-XX: Having had both its target price and recommendation under review, Cantor Fitzgerald rates a target price of 13p and a buy recommendation.Carillion: UBS lowers target price from 240p to 230p and reiterates a sell recommendation.Chime Communications: Investec ups target price from 265p to 300p and keeps a buy recommendation.Clinigen Group: Numis revises target price from 265p to 310p and stays with its buy recommendation.Cobham: Morgan Stanley ups target price from 175p to 195p and maintains an underweight rating. Exane BNP moves target price from 205p to 230p, while staying with its neutral rating.Daily Internet: Merchant Securities initiates with a target price of 8p and a buy recommendation.Dixons Retail: Deutsche Bank shifts target price from 31p to 36p keeping a buy recommendation.Escher Group: Panmure Gordon increases target price from 384p to 410p, while maintaining a buy recommendation.GlaxoSmithKline: Deutsche Bank increases target price from 1440p to 1530p and retains a hold recommendation. Espirito Santo shifts target price from 525p to 533p, while keeping a neutral rating.Hammerson: UBS moves target price from 525p to 560p, while leaving its buy recommendation unchanged.Herencia Resources: WH Ireland downgrades from buy to a speculative buy.HG Capital Trust: Oriel Securities revises target price from 1065p to 1130p and stays with its hold recommendation.Hiscox: Westhouse Securities ups target price from 525p to 533p reiterating a neutral rating.Howden Joinery: Numis raises target price from 245p to 260p keeping an add rating.HSBC Holdings: Exane BNP cuts target price from 850p to 825p and stays with its outperform rating.Hunting: Liberum Capital raises target price from 770p to 826p, while its hold recommendation is kept.ICAP: UBS reduces target price from 330p to 305p and downgrades from neutral to sell.IMI: UBS revises target price from 1000p to 1100p, but still recommends selling.Intu Properties: Espirito Santo reduces target price from 320p to 295p keeping a sell recommendation.Ladbrokers: Panmure Gordon raises target price from 195p to 219p, while maintaining a hold recommendation. Bank of America moves target price from 235p to 260p and retains its buy recommendation.Lloyds Banking Group: Bank of America shifts target price from 65p to 70p and retains its buy recommendation.Marshalls: Citigroup moves target price from 96p to 110p staying with its neutral rating.Perform: JP Morgan raises target price from 416p to 451p and keeps its neutral rating.Petro Matad: Westhouse Securities upgrades from add to buy with a target price of 15p.Playtech: Deutsche Bank takes target price from 550p to 650p and stays with its buy recommendation.Pure Water: WH Ireland shifts target price from 8.25p to 9.75p and maintains a buy recommendation.Reckitt Benckiser: Bank of America raises target price from 5000p to 5250p and reiterates its buy recommendation.Sage: Analysts at Bank of America-Merrill Lynch have downgraded their view to underperform. Bank of America shifts target price from 320p to 330p, while downgrading to underperform.Schroders: Credit Suisse ups target price from 1800p to 2150p keeping a neutral rating.Standard Chartered: Exane BNP revises target price from 1700p to 1750op leaving its neutral rating unchanged.Standard Life: Bank of America increases target price from 340p to 375p keeping an underperform rating.SThree: Numis downgrades to hold with a target price of 350p.St Ives: Numis moves target price from 132p to 150p reiterating its buy recommendation.St Modwen Properties: Numis revises target price from 259p to 280p and downgrades to add.Tullet Prebon: UBS shifts target price from 244p to 250p, while downgrading from neutral to sell.UBM: UBS ups target price from 700p to 740p and reiterates a neutral rating. Citigroup moves target price from 734p to 749p, while its neutral rating is kept.William Hill: Bank of America takes target price from 315p to 420p and leaves its underperform rating unaltered.Wolseley: UBS raises target price from 2800p to 3375p and keeps a neutral rating.
More News
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.